Status:
COMPLETED
Study of Forceps Cannulation During ERCP
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Conditions:
Post-ERCP Acute Pancreatitis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A difficult cannulation has been identified as one of the high risk factors for developing post-ERCP pancreatitis (PEP). The accessibility and morphology of the papilla influence the level of cannulat...
Detailed Description
Endoscopic retrograde cholangiopancreatography (ERCP), an invasive procedure that combines endoscopy and x-ray to treat issues with the bile and pancreatic ducts, carries a two to ten percent risk of ...
Eligibility Criteria
Inclusion
- PRIMARY INCLUSION CRITERIA:
- Patient consent
- ERCP done on native papilla
- SECONDARY INCLUSION CRITERIA:
- Papilla in a diverticulum
- Papilla on rim of a diverticulum
- Difficult cannulation (5 attempts, 5 minutes, or 2 unintended PD wire passages)
- Redundant tissue overlying papilla
- Type 2, 3, or 4 papilla
Exclusion
- Prior ampullectomy
- Known pregnancy, positive test, breastfeeding
- Clinical contraindication to ERCP
- Metal allergy
- Prior sphincterotomy
- Inability to follow protocol
- \<18 years old
- Enrolled in another ERCP study
- Biliary/PD stent in place
Key Trial Info
Start Date :
May 12 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 21 2024
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT05336630
Start Date
May 12 2022
End Date
October 21 2024
Last Update
October 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dartmouth Health
Lebanon, New Hampshire, United States, 03756